PMID- 15949597
OWN - NLM
STAT- MEDLINE
DCOM- 20051201
LR  - 20221207
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 49
IP  - 1
DP  - 2005 Jul
TI  - Sequential therapy with Vinorelbine followed by Gemcitabine in patients with 
      metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or 
      elderly with comorbidities--a multicenter phase II trial.
PG  - 117-23
AB  - BACKGROUND: High risk patients with metastatic non small cell lung cancer (NSCLC) 
      including patients with performance status (PS) 2 or elderly with comorbidities 
      do poorly on combination chemotherapy regimens. We evaluated a sequential 
      treatment with Vinorelbine followed by Gemcitabine to determine its effect on 
      survival and the toxicity in this patient population. METHODS: Forty-two 
      evaluable patients, median age 75, 21 patients with PS 2 and 21 patients with PS 
      0 or 1, 37 patients with stage IV and five patients with stage III B NSCLC 
      entered the trial. They received Vinorelbine 30 mg/m2, i.v., on days 1+8 every 3 
      weeks followed by Gemcitabine 1000 mg/m2, i.v., on days 1+8 every 3 weeks, each 
      for two cycles for stable disease or one cycle after best response. Then stable 
      patients continued until progressive disease on Vinorelbine or Gemcitabine 
      according to the patient's preference. RESULTS: A total of 126 cycles of 
      Vinorelbine were administered to 42 patients, median of three cycles per patient 
      and 74 cycles of Gemcitabine, median of 1.0 cycle per patient. Sixteen patients 
      (38%) achieved PR, 11 patients on Vinorelbine, 5 patients on Gemcitabine; 12 
      patients (26%) had stable disease, 7 patients on Vinorelbine, 5 patients on 
      Gemcitabine. Of 24 patients with progressive disease on Vinorelbine, 3 patients 
      (12.5%) responded to Gemcitabine. Median time-to-first progression was 3.5 
      months, median survival was 8 months, 1-year survival was 12 patients (28.5%). No 
      grade 3 or 4 toxicities were reported. CONCLUSION: This sequential treatment 
      offers excellent palliative treatment with minimal toxicity for high-risk 
      patients with metastatic NSCLC.
FAU - Hirsh, Vera
AU  - Hirsh V
AD  - Royal Victoria Hospital, McGill University, 687 Pine Avenue W, Montreal, Que., 
      Canada H3A 1A1. vera.hirsh@muhc.mcgill.ca
FAU - Latreille, Jean
AU  - Latreille J
FAU - Kreisman, Harvey
AU  - Kreisman H
FAU - Desjardins, Pierre
AU  - Desjardins P
FAU - Ofiara, Linda
AU  - Ofiara L
FAU - Whittom, Renaud
AU  - Whittom R
FAU - Fox, Susan
AU  - Fox S
FAU - Palayew, Mark David
AU  - Palayew MD
FAU - Pintos, Javier
AU  - Pintos J
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20050216
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0W860991D6 (Deoxycytidine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - Q6C979R91Y (Vinorelbine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/complications/*radiotherapy
MH  - Comorbidity
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Drug Administration Schedule
MH  - Female
MH  - *Frail Elderly
MH  - Humans
MH  - Infusions, Intravenous
MH  - Lung Neoplasms/complications/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Palliative Care
MH  - Risk Factors
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vinblastine/administration & dosage/analogs & derivatives
MH  - Vinorelbine
MH  - Gemcitabine
EDAT- 2005/06/14 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/06/14 09:00
PHST- 2004/07/28 00:00 [received]
PHST- 2004/11/17 00:00 [revised]
PHST- 2004/11/23 00:00 [accepted]
PHST- 2005/06/14 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/06/14 09:00 [entrez]
AID - S0169-5002(04)00623-3 [pii]
AID - 10.1016/j.lungcan.2004.11.029 [doi]
PST - ppublish
SO  - Lung Cancer. 2005 Jul;49(1):117-23. doi: 10.1016/j.lungcan.2004.11.029. Epub 2005 
      Feb 16.